On June 17, Korea Investment & Securities recognized Celloid as a potential game changer in the organoid market. Celloid is gaining significant attention for its innovative solutions.
The organoid industry is poised for rapid growth, driven by the expansion of the advanced regenerative medicine sector and regulatory shifts such as the U.S. FDA’s phased elimination of animal testing. Demand for organoids is rising as they become essential platforms for developing and validating regenerative therapies, and their adoption is expected to grow as a reliable alternative to animal testing.
With its proprietary technology enabling the stable production of high-quality organoids, Celloid is positioned to be a key player in this expanding market.
Go to link
Celloid has signed a MOU with EDmicBio, a company specializing in the development of 3D organ-on-a-chip systems using its own in-house 3D bioprinting technology.
This agreement represents a strategic open innovation model between two leading Korean biotech companies, centered around organoids and bioprinting—key technologies driving the future of the bioindustry. The collaboration aims to co-develop liver organoids by integrating liver tissue-derived bioink with automated 3D cell culture technology.
Dong Sung Kim, CEO of Celloid, was featured in an interview with BIOTIMES. Celloid’s groundbreaking 3D cell culture platform has started to gain attention in the advanced biotechnology industry.
Our innovative technology is enabling the scalable production of high-quality organoids with consistent reproducibility and relevance.
Go to link
Finally, our versatile 3D cell culture systems, OrgaNest® Basic+ with NestWell®, have been adopted at
-
Toxicological Research Division of National Institute of Food & Drug Safety Evaluation(NIFDS), Ministry of Food and Drug Safety(MFDS).
-
Seoul Asan Medical Center
How impressive! We are improving the system’s functionality by operating the currently installed equipment and generating valuable collaborative outcomes.
Celloid has signed a Memorandum of Understanding (MOU) with YiPSCELL, a company specializing in the development of regenerative therapies based on induced pluripotent stem cells (iPSCs).
Through this partnership, the two companies will collaborate on developing organoid-based regenerative therapies, with a particular focus on treatments for cartilage and liver diseases. Their goal is to provide personalized treatment solutions in the field of advanced regenerative medicine by leveraging 3D cell culture automation technology.
Go to link
Our versatile 3D cell culture systems, NestWell® and OrgaNest® Basic+, have been installed at the Stem Cell Convergence Research Center of KRIBB, Korea Research Institute of Bioscience and Biotechnology.
We are eager to explore the impressive collaborative research outcomes that our solutions can facilitate.
Dong Sung Kim, CEO of Celloid, delivered an impressive talk titled ‘Development of an Automated Cell Culture System for Organoid Standardization’ at the Joint Symposium on the Expansion of Biohealth Standardization Utilization, organized by the Korea Food and Drug Administration and the National Institute of Standards and Technology.
Go to link
Exciting news: the 3D cell culture system, “OrgaNest®,” has officially launched and is now installed at the Center for 3D Organ Printing and Stem Cells at POSTECH.
We eagerly await updates on the innovative research being conducted with OrgaNest® in Pohang!
On October 16th, Celloid hosted the second-year workshop for the research project titled “Development of a 3D Bioreactor for In Situ Formation of Uniform Cell Aggregation, Proliferation, and Differentiation Using a Permeable Membrane Scaffold and Flow-Through System,” supported by South Korea’s Ministry of Trade, Industry and Energy.
Researchers from Celloid, Yipscell, KAIST, Samsung Medical Center, and Asan Medical Center participated in the workshop to discuss the next steps in research and development, based on the progress made to date.
Copyright by Celloid 2023. All rights reserved.
Copyright by Celloid 2023. All rights reserved.